Preotact (parathyroid hormone (rDNA))
- Region
- 🇪🇺 EU
- Active substance
- parathyroid hormone (rDNA)
- Company
- NPS Pharma Holdings Limited
- Status
- Withdrawn
- Therapeutic area
- Osteoporosis, Postmenopausal
- EU approval
- Mon 24 Apr 2006
- Application
- EMEA/H/C/000659
- ATC
- H05AA03
- Official record
- www.ema.europa.eu
Indication
Treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1). A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
Regulatory milestones
No milestones recorded in the last year.
Follow Preotact
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.